Pharmaron Beijing Co Ltd
HKEX:3759

Watchlist Manager
Pharmaron Beijing Co Ltd Logo
Pharmaron Beijing Co Ltd
HKEX:3759
Watchlist
Price: 21.04 HKD -3.13% Market Closed
Market Cap: HK$60.2B

EV/GP

10.9
Current
8%
Cheaper
vs 3-y average of 11.8

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
10.9
=
Enterprise Value
HK$54.4B
/
Gross Profit
¥4.9B

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
10.9
=
Enterprise Value
HK$54.4B
/
Gross Profit
¥4.9B

Valuation Scenarios

Pharmaron Beijing Co Ltd is trading below its 3-year average

If EV/GP returns to its 3-Year Average (11.8), the stock would be worth HK$22.96 (9% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+33%
Average Upside
24%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 10.9 HK$21.04
0%
3-Year Average 11.8 HK$22.96
+9%
5-Year Average 14.5 HK$28.02
+33%
Industry Average 14 HK$27.19
+29%
Country Average 13.6 HK$26.31
+25%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
CN
Pharmaron Beijing Co Ltd
HKEX:3759
52.1B HKD 10.9 31.3
US
PerkinElmer Inc
LSE:0KHE
936.1B USD 599.5 3 881
US
Thermo Fisher Scientific Inc
NYSE:TMO
174.4B USD 11.4 25.5
US
Danaher Corp
NYSE:DHR
124B USD 9.3 33.6
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 32.4 46.1
CN
WuXi AppTec Co Ltd
SSE:603259
326.9B CNY 13.5 17.1
CH
Lonza Group AG
SIX:LONN
32.9B CHF 10.1 -119.6
US
Agilent Technologies Inc
NYSE:A
32.4B USD 9.1 25.1
US
Waters Corp
NYSE:WAT
30.1B USD 16.3 46.9
US
IQVIA Holdings Inc
NYSE:IQV
26.8B USD 7.1 19.8
US
Mettler-Toledo International Inc
NYSE:MTD
25.8B USD 11.6 29.7

Market Distribution

In line with most companies in China
Percentile
49th
Based on 6 967 companies
49th percentile
13.2
Low
0 — 8
Typical Range
8 — 23.3
High
23.3 —
Distribution Statistics
China
Min 0
30th Percentile 8
Median 13.6
70th Percentile 23.3
Max 17 898 541.1

Pharmaron Beijing Co Ltd
Glance View

Pharmaron Beijing Co Ltd., a dynamic player in the biotech and pharmaceutical services sector, has carved a niche by capitalizing on the demand for comprehensive R&D services. Founded in 2004, the company emerged at a time when global pharmaceutical companies were grappling with skyrocketing research costs and the increasing complexity of drug development. Pharmaron offers a broad spectrum of services across the drug discovery and development pipeline, including laboratory services, chemistry, biology, and pharmacology, effectively monetizing its expertise by partnering with global pharmaceutical firms. By providing integrated solutions that cover the entire span of research, from preclinical development to commercial manufacturing, Pharmaron positions itself as an indispensable ally for companies aiming to streamline their product development journeys. The company’s revenue model thrives on long-term partnerships and collaborations with some of the industry's leading pharmaceutical and biotech firms. Using a client-centric approach, Pharmaron aligns its capabilities with customer needs, ensuring scalable and customizable service offerings. This close alignment not only enhances client satisfaction but also encourages repeat business, fostering a cycle of sustainable revenue growth. In recent years, Pharmaron has been expanding its geographical footprint and service capacity through strategic acquisitions and investments in state-of-the-art facilities and technologies, aiming to bolster its position in key markets across the US, Europe, and China. As the pharmaceutical landscape continues to evolve, Pharmaron leverages its robust R&D service portfolio and strategic alliances to maintain its growth trajectory amidst a backdrop of increasing globalization and technological advancement in the industry.

Intrinsic Value
28.82 HKD
Undervaluation 27%
Intrinsic Value
Price HK$21.04
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett